Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Kudo-Saito, J. Schlom, K. Camphausen, C. Coleman, J. Hodge (2005)The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established Tumors
Clinical Cancer Research, 11
SA Rosenberg, BS Packard, PM Aebersold (1988)Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma
A preliminary report. N Engl J Med, 319
M. Dudley, J. Wunderlich, J. Yang, P. Hwu, D. Schwartzentruber, S. Topalian, R. Sherry, F. Marincola, S. Leitman, C. Seipp, Linda Rogers-Freezer, K. Morton, Azam Nahvi, S. Mavroukakis, D. White, S. Rosenberg (2002)A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma
Journal of Immunotherapy, 25
S Hori, T Nomura, S Sakaguchi (2003)Control of regulatory T cell development by the transcription factor FOXP3
D. Lenschow, T. Walunas, J. Bluestone (1996)CD28/B7 system of T cell costimulation.
Annual review of immunology, 14
I. Caras, A. Grigorescu, C. Stăvaru, D. Radu, I. Mogos, G. Szegli, A. Salageanu (2004)Evidence for immune defects in breast and lung cancer patients
Cancer Immunology, Immunotherapy, 53
V. Trouet, Jan Esper, Nicholas Graham, Andy Baker, J. Scourse, David, C. Frank (2002)Supporting Online Material
M. Katoh (2002)Expression of human SOX7 in normal tissues and tumors.
International journal of molecular medicine, 9 4
R. Angulo, D. Fulcher (1998)Measurement of Candida-specific blastogenesis: comparison of carboxyfluorescein succinimidyl ester labelling of T cells, thymidine incorporation, and CD69 expression.
Cytometry, 34 3
田畑 智之 (2004)Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers
Y Yamaguchi, A Ohshita, Y Kawabuchi (2003)Adoptive immunotherapy of cancer using activated autologous lymphocytes?current status and new strategies
Hum Cell, 16
J. Dannull, Z. Su, D. Rizzieri, Benjamin Yang, Doris Coleman, Donna Yancey, A. Zhang, P. Dahm, N. Chao, E. Gilboa, J. Vieweg (2005)Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
The Journal of clinical investigation, 115 12
J. Shimizu, S. Yamazaki, S. Sakaguchi (1999)Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
Journal of immunology, 163 10
A. Aruga, K. Yamauchi, K. Takasaki, Takaji Furukawa, F. Hanyu (1991)Induction of autologous tumor‐specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization
International Journal of Cancer, 49
M. Okawaki, Y. Yamaguchi, R. Okita, M. Ôhara, M. Okada (2008)Dose-finding study of anti-CD25 antibody for targeting regulatory T cells in locoregional immunotherapy of malignant effusion.
Hiroshima journal of medical sciences, 57 1
S Read, V Malmstrom, F Powrie (2000)Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4 (+) regulatory cells that control intestinal inflammation
J Exp Med, 192
Takeshi Takahashi, Tomoyuki Tagami, S. Yamazaki, T. Uede, J. Shimizu, N. Sakaguchi, T. Mak, S. Sakaguchi (2000)Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4
The Journal of Experimental Medicine, 192
S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, M. Toda (1995)Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
Journal of immunology, 155 3
GQ Phan, JC Yang, RM Sherry (2003)Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Proc Natl Acad Sci USA., 100
S. Rosenberg, B. Packard, P. Aebersold, D. Solomon, S. Topalian, S. Toy, P. Simon, M. Lotze, James Yang, C. Seipp, Colleen Simpson, C. Carter, S. Bock, D. Schwartzentruber, John Wei, D. White (1988)Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
The New England journal of medicine, 319 25
M. Dudley, J. Wunderlich, J. Yang, R. Sherry, S. Topalian, N. Restifo, R. Royal, U. Kammula, D. White, S. Mavroukakis, L. Rogers, Gerald Gracia, S. Jones, David Mangiameli, M. Pelletier, J. Gea-Banacloche, M. Robinson, D. Berman, A. Filie, A. Abati, S. Rosenberg (2005)Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 10
K. Kono, Akihiro Takahashi, H. Sugai, H. Fujii, A. Choudhury, R. Kiessling, Y. Matsumoto (2002)Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, 8 11
A Aruga, K Yamauchi, K Takasaki (1991)Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer
Int J Cancer, 49
G. Phan, J. Yang, R. Sherry, P. Hwu, S. Topalian, D. Schwartzentruber, N. Restifo, Leah Haworth, C. Seipp, Linda Freezer, K. Morton, S. Mavroukakis, P. Duray, S. Steinberg, J. Allison, T. Davis, S. Rosenberg (2003)Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Proceedings of the National Academy of Sciences of the United States of America, 100
D. Boczkowski, S. Nair, D. Snyder, E. Gilboa (1996)Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
The Journal of Experimental Medicine, 184
A. Rowshani, A. Uss, S. Yong, R. Lier, I. Berge (2004)Effects of CD25 monoclonal antibody on proliferative and effector functions of alloactivated human T cells in vitro
European Journal of Immunology, 34
P. Waterhouse, J. Penninger, E. Timms, A. Wakeham, A. Shahinian, Kelvin Lee, C. Thompson, H. Griesser, T. Mak (1995)Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
S. Rosenberg, M. Lotze, L. Muul, S. Leitman, A. Chang, S. Ettinghausen, Y. Matory, J. Skibber, E. Shiloni, J. Vetto, C. Seipp, Colleen Simpson, C. Reichert (1985)Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
The New England journal of medicine, 313 23
S. Read, V. Malmström, F. PowrieBrief Definitive Report Cytotoxic T Lymphocyte–associated Antigen 4 Plays an Essential Role in the Function of Cd25 Ϩ Cd4 Ϩ Regulatory Cells That Control Intestinal Inflammation
Functional modulation of regulatory T cells (T-regs) is one possible approach to cancer immunotherapy. In this study, we investigated whether low-dose basiliximab, a chimeric anti-CD25 monoclonal antibody, could suppress the T-regs function not by depletion but by inactivation, and increase immune responses. Peripheral blood mononuclear cells from healthy donors and patients with malignancy were collected. We tried T-regs inactivation using various concentrations of basiliximab before induction of lymphokine-activated killer (LAK) cells. We measured cell proliferation, lymphocyte phenotype, intracellular T-regs maker, and Th1/2 cytokines production. Our results showed that the optimal concentration of basiliximab for specifically down-modulating only T-regs was 0.001 μg/ ml. The reduction of Th-2 cytokine secretion with concomitant APC induction without suppressing cell proliferation offers the promise of a novel adoptive immunotherapy to cancer patients.
Targeted Oncology – Springer Journals
Published: Nov 11, 2008
Access the full text.
Sign up today, get DeepDyve free for 14 days.